Clinical use of current polygenic risk scores may exacerbate health disparities
By Alicia R. Martin, M. Kanai, Y. Kamatani, Y. Okada, Benjamin M. Neale, Mark J. Daly. 2019
2,286 citations recorded by the source corpus.
Polygenic risk scores (PRS) are poised to improve biomedical outcomes via precision medicine. However, the major ethical and scientific challenge surrounding clinical implementation of PRS is that those available today are several times more accurate in individuals of European ancestry than other ancestries. This disparity is an inescapable consequence of Eurocentric biases in genome-wide association studies, thus highlighting that—unlike clinical biomarkers and prescription drugs, which may individually work better in some populations but do not ubiquitously perform far better in European populations—clinical uses of PRS today would systematically afford greater improvement for European-descent populations. Early diversifying efforts show promise in leveling this vast imbalance, even when non-European sample sizes are considerably smaller than the largest studies to date. To realize the full and equitable potential of PRS, greater diversity must be prioritized in genetic studies, and summary statistics must be publically disseminated to ensure that health disparities are not increased for those individuals already most underserved. This Perspective discusses scientific and ethical considerations regarding the clinical use of polygenic risk scores, highlighting the pressing need to diversify cohorts for genetic studies beyond European-ancestry populations.
Subfields: Genetics, AI Ethics, Fairness & Society, Medical & Health AI
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Alkes L Price
- Gonçalo R. Abecasis
- Jian Yang
- Hilary K Finucane
- Christian Fuchsberger
- Cristen J. Willer
- Michael Boehnke
- Michael Inouye
In AI Ethics, Fairness & Society
In Medical & Health AI
Citations in the corpus
- Ethical Machine Learning in Healthcare (2020, background): “Larger genomics datasets often target European populations, producing genetic risk scores which are more accurate in individuals of European ancestry than other ancestries (75).”
- Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. (2019, positive): “Genetic risk prediction attenuates with increasing divergence between the discovery and target populations, indicating that polygenic risk scores (PRSs) based on Eurocentric GWASs are not equally predictive when applied to non-European populations (Duncan et al., 2019; Martin et al., 2019).”
- The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource (2022, background): “Benefits from improved knowledge of SNP-trait associations accruing from GWAS and PGS are diluted, leading to health inequities for under-represented populations (20,21).”
- The power of genetic diversity in genome-wide association studies of lipids (2021, background): “Although many traits show a high degree of shared genetic correlation across ancestries 32,36,37 , others have distinct genetic variants with large effects that are more common in specific ancestry groups 34 , which may limit the utility of multi-ancestry PRS for particular phenotypes in some…”